Virax Biolabs Group Ltd Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
Analyst Coverage
1analyst covering
FY EPS (est.)
-$6.00next fiscal year
Reporting Calendar
| Event | Expected Date |
|---|---|
| Larger Clinical Validation Analysis (300 participants) Commencement | 31 Dec 2026 |
| Larger Clinical Validation Results Release | 31 Mar 2027 |
Monitoring Framework
Key Performance Indicators
ViraxImmune Pilot Dataset Specificity Annually0.9Target: Maintain high specificity (>85%) in larger clinical validation
ViraxImmune Pilot Dataset Positive Predictive Value (PPV) Annually0.9Target: Maintain high PPV in larger clinical validation
Cash and Cash Equivalents (USD) Quarterly6.4MTarget: Sufficient working capital to fund clinical validation and LDT launch
Watch Items
- U.S. Clinical Validation Study with Emory UniversityTrigger: Initiation of patient enrollment and sample collectionAction: Monitor progress updates in SEC Form 6-K filings and press releases
- U.S. Market Entry via Laboratory Developed Test (LDT) RouteTrigger: Submission of LDT validation data to CLIA-certified laboratory partnersAction: Evaluate commercial partnership agreements and timeline to launch
- Share Consolidation (Reverse Split)Trigger: Implementation of the approved 1-for-10 to 1-for-30 reverse splitAction: Verify final consolidation ratio and effective date to ensure Nasdaq minimum bid price compliance
Research as of 20 Jun 2026